The by far bluntest and most disputed formof is the gradated cost division however „purchase price calculation, “so called, because the insurer only patient for the price of a relatively inexpensive drug in a larger „therapeutic group “of drugs, which are explained completely, in order „equivalent “to be returned (L ´ opez Casasnovas and Puig Junoy 2001). Patients are then requested, the entire difference between this inexpensive purchase price and the actual retail price, which are computed for a drug to pay with a higher price from bag. Purchase price calculation was used under Germany legal Krankenversicherungsystem since at the beginning of the 90's. It is used now in some other countries and closes in some Canadian provinces, in Australia and in New Zealand (Kanavos and Reinhardt 2003). As already noticed, the republican politics policy (2003, segregated P. 5) purchase price calculation as a form delimitation of the free international trade, although on its face purchase prices strike at least some economists (Huskamp et al. 2000; _ Kanavos and Reinhardt 2003) as appropriate precondition for a genuine, price competitive market for pharmaceutical product, particularly if patient and it physician wave informedabout the clear attribute and relative the profitability the drug within a therapeutic group. The idea is that insurance hoisting engines socialize the costs only the fundamental use up-requiring medicines, which are considered to it as sufficient and the suppliers of the more expensive replacement into a therapeutically equivalent group left, in order to convince patients in a free market by full covering that the use of the more expensive products is the out OF pocket extra charge on them. The approach is not anything differently than the correspondence of the more general concept „the defined contribution “now far recommended of many economists for the purchase of the health insurance (Pauly et al. 1991). Under this approach government or employers forms a defined contribution to the purchase of an individual of the private health insurance and leaves the individual, in order to pay the full difference between this contribution and the insurance premium, which are really loaded of the private insurer. Remarkably however economists can be found, who committee the idea of the purchase price calculation on two ground (you e.g. see 2000 and 2001 and the row to Danzon of the attempts in L´ opez Casasnovas and in J¨onsson 2001). This opposition comes even of the economists, who prefer the idea of the defined contributions for health insurance (you e.g. see, co-authors in Pauly et al. to Danzon. 1991). First these economists argued that patients usually over the profitability of the rivaling drugs in a therapeutic does not inform enough werdenRemarkably, more however, economists CAN fuel element found who reject the idea OF reference pricing on two grounds (lake, e.g., Danzon 2000 and 2001, and the series OF essay in L´ opez Casasnovas and J¨onsson 2001). That opposition of comes of even from economists who favor the idea OF defined contributions for health insurance (lake, e.g., Danzon, coauthor in Pauly et al. 1991). Roofridge, thesis economists have argued that patients typically acres emergency sufficiently informed about the cost effectiveness OF rival drugs in A therapeutic